Business Description
Sareum Holdings plc is a UK-based drug development company focused on creating treatments for cancer and autoimmune diseases. Its most advanced asset, SDC-1801, has completed Phase 1 trials as a potential autoimmune therapy, while SRA737 has progressed through Phase 2 trials targeting cancer cell replication. The company also has earlier-stage programs in development and recently entered a collaboration with Receptor.AI to speed up the discovery of a new class of inhibitors that can reach the brain, with initial results expected by late 2025. Founded in 2004 and headquartered in Cambridge, England, Sareum operates under its current name after rebranding from Keepfast plc.
